Pinealon (brain / cortical bioregulator)
Khavinson tripeptide (Glu-Asp-Arg) positioned as a brain and cognitive bioregulator.
At a glance
What it is: Khavinson tripeptide (Glu-Asp-Arg) positioned as a brain and cognitive bioregulator..
Primary research applications:
- Cognitive support research (Khavinson framework)
- Pineal and circadian-rhythm contexts
- Brain-aging discussion in originating tradition
Editorial summary: Pinealon is the most-discussed brain-targeted entry in the Khavinson short-peptide framework — a tripeptide (Glu-Asp-Arg) positioned for cognitive support and pineal/circadian-related aging. Same lineage-concentrated evidence pattern as the rest of the family, but with somewhat broader user-community awareness.
- Class / structure
- Tripeptide (Glu-Asp-Arg) — Khavinson cytogen short peptide
- Half-life
- Very short systemic half-life
- First described
- Khavinson group, late 1990s / early 2000s
- Regulatory status
- Sold as a supplement; not FDA-approved
What is Pinealon?
Pinealon is a tripeptide bioregulator positioned within the Khavinson framework as supporting brain, cognitive, and pineal-related function.
Discovery and development
Pinealon is one of the better-known Khavinson short peptides — a tripeptide of glutamate, aspartate, and arginine targeting cognitive and pineal/circadian-related function. It's frequently cited in Khavinson-tradition longevity discussions and has received more user-community attention than most of the other tissue-specific bioregulators in the framework.
Mechanism of action
Within the Khavinson framework, Pinealon is proposed to reach the cell nucleus in brain tissue and modulate gene expression in a tissue-selective way. Mechanistic specifics remain controversial outside the originating research lineage. Independent Western neuroscience has not validated the proposed direct DNA / nuclear interactions of short peptides at scale.[1]
Pharmacokinetics
Very short plasma half-life consistent with the Khavinson short-peptide family. The framework's proposed mechanism — tissue-specific direct signaling rather than sustained systemic action — accounts for the apparent disconnect between brief plasma exposure and reported effects.
What the research shows
The peer-reviewed literature on Pinealon is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Selectively supports brain and cognitive function as a bioregulator | Khavinson framework hypothesis | Uncertain |
| Improves sleep architecture and circadian function | Originating-group reports; Western RCT evidence limited | Uncertain |
| Supports cognitive longevity in healthy adults | Lineage-concentrated evidence; not established at Western evidence-grading levels | Uncertain |
Reported user experiences
How the research describes administration
Available as oral capsules in cyclic regimens. Some sources discuss intranasal administration; clinical evidence specifically for that route is limited.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Pinealon is the most-discussed brain-targeted entry in the Khavinson short-peptide framework, with a real research lineage and a substantial user community. The framework concept is intellectually interesting; the Western evidence-grading bar has not yet been cleared for the specific cognitive and longevity claims that surround the compound. Approach with curiosity tempered by recognition of the methodological gap.
Frequently asked questions
Is Pinealon related to Epitalon?
Both are Khavinson short peptides positioned for pineal-related and aging support, but they are distinct molecules. Epitalon (Ala-Glu-Asp-Gly) is the more prominent of the two in the broader Khavinson framework, with the most-cited claim being telomerase-related effects. Pinealon (Glu-Asp-Arg) is positioned more specifically for cognitive and circadian function.
Is Pinealon FDA-approved?
No. It's sold internationally as a supplement under the Khavinson product line.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. Pinealon application in elderly patients. Adv Gerontol. 2017;30(2):246-255. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+pinealon